Predictable reimbursement is a primary operational determinant of biosimilar longevity in practices, frequently outweighing ...

LAS VEGAS—Optum Rx is planning to add up to three biosimilar drugs to its formulary to compete directly with AbbVie's Humira, which accounts for massive pharmacy spend each year. Optum Rx, the ...

The report reviews the challenge of ASP erosion in Medicare Part B and policy solutions that could ensure patients have access to biosimilars.

January 31 is set to mark the start of a watershed year for the biosimilars industry with the release of Amjevita, the first biosimilar for Humira, the world’s best-selling drug. Several more Humira ...

Please provide your email address to receive an email when new articles are posted on . The substitution by pharmacies of biosimilars without additional approval from the rheumatology practitioner ...

Biosimilars play a critical role in lowering the price of prescription drugs, with the potential to save $180 billion over the next five years if the United States can increase its use over biologic ...

Cardinal Health's analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology rising in adoption and accessibility gains.

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

Complex formulary structures, high initial pricing, entrenched market advantages favoring established brands, and hesitancy among prescribers and patients have slowed adoption, leaving billions in ...

Modernizing biomanufacturing methods and reducing regulatory burdens are key landmarks on India’s roadmap for expanding biosimilars development.

The use of biosimilars in oncology and as supportive agents for patients with cancer has introduced an important opportunity to expand access to cost-effective care, but their utilization remains ...

BCBS Michigan saved $67 million and $80 million in 2024 and 2025, respectively, through biosimilar use, the insurer reported Feb. 17. The company began moving members from Humira and Stelara to ...